About
Pipeline
For patients & physicians
Investors
Contact us
About
About BerGenBio
Management Team
Board of Directors
Scientific Advisory Board
Partners
Pipeline
Pipeline overview
BEMCENTINIB | NSCLC
BEMCENTINIB | SRI
TILVESTAMAB (BGB149)
Publications
For patients & physicians
Investors
Share Information and Policies
Share Data
Largest Shareholders
Stock Exchange Notices
Analyst Coverage
News
Financial Reports
Presentations
Financial Calendar
Corporate Governance
General Meetings
Environmental social and governance - ESG
Investor Relations
Rights Issue 2023
Warrants
Contact us
Developing breakthrough AXL therapeutics to improve patients' lives
D
e
v
e
l
o
p
i
n
g
b
r
e
a
k
t
h
r
o
u
g
h
A
X
L
t
h
e
r
a
p
e
u
t
i
c
s
t
o
i
m
p
r
o
v
e
p
a
t
i
e
n
t
s
'
l
i
v
e
s
Learn About Us
Information about the Warrants
Read more
BerGenBio is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases including cancer and severe respiratory infections
Recent News
4th March 2024
BerGenBio to Participate in Carnegie Nordic Healthcare Seminar
Read more
19th February 2024
BerGenBio ASA – Approval and publication of a prospectus supplement
Read more
14th February 2024
BerGenBio’s Fourth Quarter 2023 Results: Focused Strategy Gathers Momentum
Read more
7th February 2024
BerGenBio Announces New Preclinical Data Indicating Broadened Potential for Bemcentinib to Treat Severe Respiratory Infections
Read more
6th February 2024
BerGenBio ASA: Invitation to fourth quarter 2023 results webcast
Read more
15th December 2023
BerGenBio announces closure of EU-SolidAct bemcentinib study arm in hospitalized COVID-19 patients
Read more
12th December 2023
BerGenBio to Present at DNB Nordic Healthcare Conference
Read more
11th December 2023
BerGenBio Announces Final Bemcentinib Phase 2 Data in AML and MDS Presented at the 2023 ASH Meeting
Read more
8th December 2023
BerGenBio ASA: Grant of share options
Read more
All news